K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).
暂无分享,去创建一个
J. Kowalski | K. Murphy | Richard J. Jones | B. Smith | Carole B. Miller | Y. Kasamon | H. Levitsky | B. Biedrzycki | K. Hege | C. Chia | I. Tartakovsky